Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 75-79

  Volavka, Jan ^a   Cooper, Thomas B ^c   Czobor, Pál ^c   Meisner, Morris ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NONE

Author keywords

haloperidol; negative symptoms; plasma level; schizoaffective disorder; schizophrenia

Indexed keywords

HALOPERIDOL;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DETERIORATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALOPERIDOL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0029990611     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. American Psychiatric Association. DSM-III-R: Diagnosis and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
2. Carpenter, WT Jr; Heinrichs, DW; and Alphs, LD. Treatment of negative symptoms. Schizophr. Bull. 11:440-452, 1985.
3. Carpenter, WT Jr, Heinrichs, DW; and Wagman, AM. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145:578-583, 1988.
4. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
5. Kirkpatrick, B; Buchanan, RW; McKenney, PD; Alphs, LD; and Carpenter, WT Jr. The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia. Psychiatry Res. 30:119-123, 1989.
6. Overall, JE, and Gorham, DR. Introduction - The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24:97-99, 1988.
7. Simpson, GM, and Angus, JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (Suppl.):11-19, 1970.
8. Volavka, J; Cooper, T; Czobor, P; Bitter, I; Meisner, M; Laska, E; Gastanaga, P; Krakowski, M; Chou, JC-Y; Crowner, M; and Douyon, R. Haloperidol blood levels and clinical effects. Arch. Gen. Psychiatry 49:354-361, 1992.
9. Volavka, J; Cooper, TB; Czobor, P; and Meisner, M. Haloperidol plasma levels and clinical effects in schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 52:837-845, 1995.